Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas

Author： Hedström J.   Haglund C.   Leinonen J.   Nordling S.   Stenman U.-H.  

Publisher： Informa Healthcare

ISSN： 0036-5513

Source： Scandinavian Journal of Clinical and Laboratory Investigation, Vol.61, Iss.2, 2001-04, pp. : 111-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Are Biliary Tract and Gallbladder Carcinomas Treatable with Irinotecan?

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-05 ,pp. : 29-30

Karger

Access to resources Recommend Favorite

Efficacy and Safety of S-1 Monotherapy in Patients with Advanced Biliary Tract Adenocarcinoma

By  

Oncology, Vol. 76, Iss. 2, 2009-01 ,pp. : 126-132

Karger

Access to resources Recommend Favorite

S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer

By  

Oncology, Vol. 77, Iss. 1, 2009-06 ,pp. : 71-74

Karger

Access to resources Recommend Favorite

Management of Complicated Biliary‐Tract Disease in Geriatric Patients*

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 20, Iss. 11, 1972-11 ,pp. : 531-536

John Wiley & Sons Inc

Access to resources Recommend Favorite

Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

By  

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 254-261

Karger

Access to resources Recommend Favorite